Abivax (ABVX) Phase 3 Obefazimod Data Shows Maintenance Benefit in UC; Shares Fall

Abivax (Nasdaq: ABVX) announced on June 2, 2026 that its Phase 3 maintenance trial of obefazimod for moderate-to-severe ulcerative colitis met the primary endpoint, with the oral drug significantly sustaining clinical remission over placebo. Despite the positive readout, shares declined in early trading, signaling investor disappointment that the efficacy magnitude did not surpass elevated expectations. The study enrolled patients who had responded to induction therapy. The company said detailed data would be presented at an upcoming medical meeting and submitted to regulators. Analysts noted that while the trial succeeded, the benefit's scale and emerging safety signals could weigh on obefazimod's competitiveness in a crowded inflammatory bowel disease market. Abivax plans to seek approval based on the results.